Gilead Sciences Inc (GILD)

71.26
0.74 1.00
NASDAQ : Health Care
Prev Close 70.52
Open 71.06
Day Low/High 70.72 / 71.76
52 Wk Low/High 77.92 / 120.37
Volume 14.02M
Avg Volume 8.13M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 92.10B
EPS 10.10
P/E Ratio 7.45
Div & Yield 2.08 (3.00%)

Latest News

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

The stock has been on fire.

2 Recovering Biotech Names With Room to Run

2 Recovering Biotech Names With Room to Run

There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.

European CHMP Adopts Positive Opinion For Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Cramer: Today's Market Emotion - Group Hug!

Cramer: Today's Market Emotion - Group Hug!

Banks, tech and healthcare are all seeing renewed buying.

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

All the Rallying Big Bank Stocks Look Very Risky, Doug Kass Says

Doug Kass shares his thoughts on Apple, Google and Starbucks.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest

If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.

Gilead Submits New Drug Application To U.S. Food And Drug Administration For Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For HIV Treatment

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.

Income Seeker: Ex-Dividend Stocks Next Week Include Coca-Cola, Gilead

Coca-Cola, Gilead and World Wrestling Entertainment are among the companies going ex-dividend next week.

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Jim Cramer is bullish on Advanced Micro Devices, Micron Technology, and Charles River Labs.

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Jim Cramer has the game plan for next week, including earnings from Thor Industries and HD Supply.

European Stocks See New Peaks in Volatile Session

European Stocks See New Peaks in Volatile Session

While causing upset among politicians and some business leaders, President Donald Trump's withdrawal of the U.S. from the Paris Agreement helped boost stock prices across the chemicals and automotive sectors.

GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment

GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment

Glaxo was boosted Friday after its HIV joint-venture filed an application in the U.S. and EU for a new combination tablet, in a continued push for dominance in the field

European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data

European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data

European stocks were mixed Wednesday as investors responded to a mixture of M&A speculation, economic data and other individual company news.

Gilead Sciences To Present At The 37th Annual William Blair Growth Stock Conference On Tuesday, June 13

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

European Stocks Fall as Politics Takes Center Stage

European Stocks Fall as Politics Takes Center Stage

European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.

GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead

GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead

GlaxoSmithKline shares outperformed the market Tuesday after clinical trials data for Gilead's Bictegravir HIV treatment appeared to reduce the threat of a superior rival to GSK's Dolutegravir.

Gilead's Investigational Fixed-Dose Combination Of Bictegravir, Emtricitabine And Tenofovir Alafenamide For The Treatment Of HIV-1 Meets Primary Endpoint In Four Phase 3 Studies

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and...

Tanger Factory Outlet Centers, Gilead Sciences, Qorvo: 'Mad Money' Lightning Round

Tanger Factory Outlet Centers, Gilead Sciences, Qorvo: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Tanger Factory Outlet Centers, Gilead Sciences, and Qorvo in the 'Mad Money' Lightning Round.

Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17)

Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17)

Ahead of Fed's June meeting, investors will need to start paying close attention to Fed officials and economic data.

Barclays Remains Bullish on Gilead

Barclays Remains Bullish on Gilead

Shares of the biopharmaceutical firm are lower by over 10% year-to-date.

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Gilead Sciences, Inc. is the #56 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

Trump Resurrects Talk of 10% Tax Holiday in Big Gift to Tech

Trump Resurrects Talk of 10% Tax Holiday in Big Gift to Tech

President Trump delivered some good news to tech giants and other corporations hoarding loads of cash abroad -- a 10% repatriation holiday is back on the table.

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

Arconic, Cedar Fair, Gilead: 'Mad Money' Lightning Round May 5 2017

A roundup of Cramer's comments on stocks of interest to viewers.